stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Return on assets
Novo Nordisk A/S's return on assets over the twelve months to 30 June 2026 was 22.0%, up 1.3 percentage points from fiscal 2025 (20.7%). Over the past ten years it has ranged from 20.7% (fiscal 2025) to 40.0% (fiscal 2016) — the current reading is the lowest in ten years. That is above the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 20.7% | (5.16) |
| FY2024 | 25.9% | (4.57) |
| FY2023 | 30.4% | 6.29 |
| FY2022 | 24.2% | (4.44) |
| FY2021 | 28.6% | (2.88) |
| FY2020 | 31.5% | (1.18) |
| FY2019 | 32.7% | (3.71) |
| FY2018 | 36.4% | (2.20) |
| FY2017 | 38.6% | (1.47) |
| FY2016 | 40.0% | 2.17 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S | 22.0% |
| AMGN Amgen Inc. compare | 10.1% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| AZN AstraZeneca PLC compare | 9.41% |
| NVS Novartis AG compare | 8.94% |
| GSK GSK PLC Sponsored ADR compare | 6.53% |
| SNY Sanofi compare | 3.24% |
| PFE Pfizer Inc. compare | 1.95% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement